Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Infectious diseases 2

Infectious Diseases

pharma-news-for-valneva-innovent-gsk-bayer

Notizia - Recent Pharma, Healthcare and Biotech Happenings

CEPI Grants $41.3 Million to Valneva; Innovent Achieves Phase III Success for Mazdutide; GSK’s BLENREP Combination Therapies EMA Review Application; Darolutamide Phase III ARANOTE Trial; Roche’s SUSVIMO Shows Long-Term Efficacy

CEPI Grants $41.3 Million to Valneva to Enhance Global Access to First Chikungunya Vaccine The Coalition for Epidemic Preparedness Innovations and Valneva SE have expanded their partnership to enhance access to the world's first chikungunya vaccine, IXCHIQ®, in Low- and Middle-Income Countries (LMICs). CEPI will provide Valneva with up to $41.3 million in additional funding over the next five years, supported by the EU’s Horizon Europe programme. This funding will support post-marketing trials and potential label extensions for children, adolescents, and pregnant women in chikungunya-endemic regions. Planned trials, set to begin in 2025, will involve several tho...

Explore More...

Immunomodulators Market and Key Applications

Harnessing the Power of Immunomodulators: Applications and Implications

Biosurgery Market Analysis

Biosurgery: Advancing Medicine through Biologically Derived Solutions

Pharma News for Nexcella, Janssen, Alentis

FDA Approves BMS’s Reblozyl for MDS; FDA Awards Orphan Drug Designation to NXC-201; Janssen Submits Supplemental NDA for Full Approval of BALVERSA; FDA Grants Fast Track Status to ALE.C04; FDA Orphan Drug Designation to Faron’s Bexmarilimab; FDA Clears IND Application for AHB-137

Pharma News for Biogen, Astellas, Ascentage

FDA Approves ZURZUVAE for Postpartum Depression; Astellas Drug Acquired in $5.9B Deal Wins FDA Approval; FDA Clearance to Phase III Study of Lisaftoclax; FDA Issues CRL to BLA Resubmission for Remestemcel-L; Bavarian Nordic Updated on its Chikungunya Virus Vaccine; FDA Orphan Drug Designation to ABM-1310

Herbal Medicine Market

What Is Herbal Medicine? A Comprehensive Exploration of Nature’s Healing Gift

Omega-3 Products Market Outlook

Evaluating the Rising Demand & the Market Potential of the Omega-3 Products

Pharma News and Updates for GSK, Gilead, ProMIS, Nucleix, PharmaTher, Vedanta Biosciences

FDA Approves GSK’s Arexvy for RSV; CHMP’s Opinion on Gilead’s Hepcludex® for HDV; FDA Clearance to ProMIS’s IND Application for PMN310; FDA Grants 501K Clearance to Bladder EpiCheck; PharmaTher Submits Fast Track Application for Ketarx to US FDA; Fast Track Designation to Vedanta Biosciences’ VE303

gsk-respiratory-syncytial-virus-vaccine

GSK Is All Set To Launch Respiratory Syncytial Virus Vaccine… Now Who’s Next?

emerging-vaccines-for-respiratory-syncytial-virus-treatment

Respiratory Syncytial Virus Treatment Market: A Complex Space Worth Billions!

epstein-barr-virus-ebv-treatment-outlook

Changing Landscape of EBV-associated Diseases Treatment: Is T-cell Immunotherapy the Answer?

Biologics in the Nasal Polyposis Treatment Market

Biologics Spark Market Interest In The Nasal Polyposis Treatment Space

mercks-gefapixant-for-crc-treatment

Will Merck’s P2X3 Receptor Antagonist for Chronic Refractory Cough Treatment Be Able to Turn FDA’s Nay Into Yea?

emerging-vaccines-for-clostridium-difficile-infection-treatment

Innovative Vaccines for Clostridium difficile Infection Treatment in the Horizon

uncomplicated-uti-treatment-landscape

Uncomplicated UTI Treatment: Challenges and Opportunities in the Market

osteomyelitis-treatment-outlook

Osteomyelitis Treatment Market: Evaluating the New Line of Therapies in the Therapeutics Space

Pharma News and Updates for AbbVie, Ferring, Merck, CSL, Amicus, Takeda

Fourth FDA Approval for AbbVie’s Vraylar; FDA Approves Ferring’s Adstiladrin for NMIBC; Merck and Moderna’s mRNA Cancer Vaccine Trial; EMA Recommends the CSL’s Gene Therapy for Hemophilia B; CHMP Backs Amicus’ Pompe Disease Therapy; Takeda Announces the Phase 3 AURORA Study Result

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly